Enhancer of zeste homolog 2 (EZH2) is a catalytic subunit of the Polycomb-repressive complex 2 (PRC2), which plays a crucial role in transcriptional repression through the methylation of histone H3 on lysine 27 (H3K27me3).

This epigenetic modification leads to chromatin compaction and gene silencing. EZH2 is frequently overexpressed in a variety of cancers, including head and neck, breast, prostate, bladder, colorectal, lung, pancreatic, melanoma, and lymphoma.

Mutations in the EZH2 gene are also prevalent in several haematological malignancies, such as B-lymphomas and follicular lymphomas.

The dual role of EZH2 as both a tumour suppressor and oncogene depending on the cancer type underscores its significance in cancer biology and therapy.

Mechanisms of EZH2 in Cancer

EZH2 influences cancer progression through various mechanisms, including promoting cell proliferation, inhibiting apoptosis, and enhancing metastatic potential.

It achieves these effects by repressing tumour suppressor genes and modulating signalling pathways that control cell growth and survival. In addition to its role in tumour cells, EZH2 affects the tumour microenvironment, particularly immune cells, contributing to an immunosuppressive milieu that favours tumour evasion from immune surveillance.

EZH2 and the tumour Microenvironment

Recent studies have highlighted the pleiotropic effects of EZH2 on both tumour and immune cells. EZH2 modulates the tumour immune microenvironment by affecting the function of various immune cells, including T cells, dendritic cells, and macrophages.

This modulation can either promote or inhibit tumour growth, depending on the context. For example, EZH2 inhibition has been shown to increase the expression of immune checkpoint molecules like PD-1, thereby enhancing the efficacy of immunotherapies.

EZH2 Inhibitors in Cancer Therapy

The development of EZH2 inhibitors (EZH2i) represents a promising therapeutic strategy.

Tazemetostat, an EZH2i, has already received FDA approval for the treatment of follicular lymphoma and epithelioid sarcoma.

Preclinical studies and clinical trials are exploring the potential of combining EZH2 inhibitors with other therapeutic modalities, such as immune checkpoint blockade (ICB) and chimeric antigen receptor T-cell (CAR-T) therapy. These combinations aim to overcome resistance to single-agent therapies and enhance antitumour immune responses.

Combining EZH2 Inhibitors with Immunotherapy

Combining EZH2 inhibitors with immunotherapies has shown synergistic effects in preclinical models. For instance, the combination of EZH2 inhibitors with PD-1 blockers has demonstrated increased macrophage toxicity and enhanced immunotherapy efficacy in malignant pleural mesothelioma.

Similarly, combining EZH2 inhibition with CAR-T therapy has improved therapeutic outcomes by boosting the expression of tumour-associated antigens in cancers like Ewing sarcoma.

These findings suggest that EZH2 inhibitors can potentiate the effects of various immunotherapeutic approaches, offering new avenues for treating resistant and refractory cancers.

Future Perspectives

Despite the advances in tumour immunotherapy, challenges remain in achieving durable responses and overcoming resistance. The heterogeneous nature of tumours and the complexity of the tumour immune microenvironment necessitate a deeper understanding of the interplay between EZH2 and immune cells.

Future research should focus on elucidating the specific mechanisms by which EZH2 modulates the immune microenvironment and identifying biomarkers to predict responses to combination therapies. Moreover, developing targeted and low-toxicity EZH2 inhibitors, possibly through nanotechnology and precision medicine approaches, holds promise for enhancing the efficacy and safety of cancer immunotherapy.

Conclusions

EZH2 plays a multifaceted role in cancer biology, influencing both tumour and immune cells. Its inhibition offers a promising strategy to enhance the efficacy of existing immunotherapies and overcome therapeutic resistance.

Ongoing research and clinical trials will continue to shed light on the optimal use of EZH2 inhibitors in combination with other treatments, paving the way for more effective and personalised cancer therapies.

The study was recently published in the Cancer Screening and Prevention.

Source: Xia & He Publishing Inc.